Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients

Ki vehet részt

• Presence of advanced active malignancy and insomnia despite nonpharmacologic management
• Anticipated hospital course of at least 3 days post randomization as judged by the patient's primary inpatient team
• One or more of the following risk factors of delirium:; Age 75 or above; Hearing impairment; Vision impairment; Initiation of 8 or new medications since start of hospitalization; Chronic kidney disease III or greater; Congestive heart failure; Hospitalization for 14 or more days; Dehydration requiring ongoing use of intravenous (IV) hydration; Electrolyte imbalance requiring ongoing correction

Ki nem vehet részt

• Current or prior delirium in the active hospitalization
• Concurrent use of strong/moderate CYP3A4 inducers and inhibitors (including but not limited to -azole antifungals, amiodarone, phenytoin, carbamazepine, etc.)
• Use of any benzodiazepine, benzodiazepine receptor modulator, or first generation antihistamine class medication within 72 hours prior to enrollment
• Personal history of narcolepsy
• Personal history of other primary sleep disorders including obstructive sleep apnea
• Personal history of alcohol use disorder
• Personal history of substance use disorder
• Personal history of cirrhosis
• History of obstructive lung disease other than asthma
• Women of childbearing potential (defined as women under age 55 without a personal history of surgical or chemotherapy-induced sterility)
• Inability to consent
• Current pregnancy
• Transaminitis more than 3 times the upper limit of normal